Clinical Trial Results:
A single-arm, open-label phase II study: Treatment beyond progression by adding Bevacizumab to XELOX or FOLFOX chemotherapy in patients with metastatic colorectal cancer and disease progression, under first-line FOLFIRI + bevacizumab combination
Summary
|
|
EudraCT number |
2009-012090-36 |
Trial protocol |
BE |
Global completion date |
16 Jan 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Feb 2016
|
First version publication date |
04 Feb 2016
|
Other versions |
|
Summary report(s) |
CTg Receipt ML22519 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.